menu
    • menu

    Company profile for Atsena Therapeutics

    NEW Drugs in Dev: 3
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness. The company has an ongoing Phase I/II clinical trial evaluating a potential therapy for one of the most common causes of blindness in children. Its pipeline of clinical and preclinical assets is powered by adeno-associated virus (AAV) technology tailored to overcome the...
    Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness. The company has an ongoing Phase I/II clinical trial evaluating a potential therapy for one of the most common causes of blindness in children. Its pipeline of clinical and preclinical assets is powered by adeno-associated virus (AAV) technology tailored to overcome the hurdles presented by inherited retinal disease, and its approach is guided by the specific needs of each patient condition.Founded by pioneers in ocular gene therapy, Atsena ,and is headquartered in North Carolina

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Atsena TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    8 Davis Drive, Suite 300, Durham, NC 27709
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://atsenatx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/atsenatx/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Genezen, Atsena Therapeutics Partner For Commercial Manufacturing
    Genezen, Atsena Therapeutics Partner For Commercial Manufacturing

    20 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/genezen-and-atsena-therapeutics-announce-strategic-commercial-manufacturing-partnership-302664886.html

    PR NEWSWIRE
    20 Jan 2026
    Share Share
    Atsena Wraps Dosing In Phase I/II/III LIGHTHOUSE Trial
    Atsena Wraps Dosing In Phase I/II/III LIGHTHOUSE Trial

    08 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/08/3215273/0/en/Atsena-Completes-Dosing-in-Part-B-of-the-Phase-I-II-III-LIGHTHOUSE-Trial-Evaluating-ATSN-201-to-Treat-X-linked-Retinoschisis-and-Announces-Plans-for-Initiation-of-Pivotal-Part-C-Co.html

    GLOBENEWSWIRE
    08 Jan 2026
    Share Share
    Atsena Therapeutics Names Mcdavid Stilwell CFO
    Atsena Therapeutics Names Mcdavid Stilwell CFO

    06 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/06/3213496/0/en/Atsena-Therapeutics-Appoints-McDavid-Stilwell-as-Chief-Financial-Officer.html

    GLOBENEWSWIRE
    06 Jan 2026
    Share Share
    Atsena Completes Adult Dosing In Atsn-201 Trial For X-Linked
    Atsena Completes Adult Dosing In Atsn-201 Trial For X-Linked

    23 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/23/3154582/0/en/Atsena-Therapeutics-Announces-Dosing-Complete-for-Adults-in-Part-B-of-the-Phase-I-II-III-LIGHTHOUSE-Trial-Evaluating-ATSN-201-to-Treat-X-linked-Retinoschisis.html

    GLOBENEWSWIRE
    23 Sep 2025
    Share Share
    Atsena Therapeutics, FDA Align on ATSN-201 Approval Path for XLRS
    Atsena Therapeutics, FDA Align on ATSN-201 Approval Path for XLRS

    09 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/09/3112470/0/en/Atsena-Therapeutics-Announces-Alignment-with-FDA-on-Regulatory-Pathway-to-Approval-for-ATSN-201-in-X-Linked-Retinoschisis-XLRS.html

    GLOBENEWSWIRE
    09 Jul 2025
    Share Share
    Atsena gene therapy hits safety goals, closes retinal splits
    Atsena gene therapy hits safety goals, closes retinal splits

    20 May 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/atsena-eye-disease-gene-therapy-hits-safety-goals-closes-retinal-splits-7-9-patients

    FIERCE BIOTECH
    20 May 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search